Regulus Therapeutics (NASDAQ:RGLS) Shares Cross Above 200-Day Moving Average of $1.61

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.61 and traded as high as $2.34. Regulus Therapeutics shares last traded at $2.26, with a volume of 101,567 shares.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RGLS. StockNews.com began coverage on shares of Regulus Therapeutics in a research note on Tuesday, April 16th. They issued a “sell” rating for the company. Leerink Partnrs reissued an “outperform” rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. Canaccord Genuity Group decreased their target price on shares of Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, March 19th. SVB Leerink started coverage on shares of Regulus Therapeutics in a research note on Monday, March 18th. They set an “outperform” rating and a $6.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Regulus Therapeutics in a research note on Monday, March 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Regulus Therapeutics Price Performance

The stock’s 50 day simple moving average is $2.15 and its two-hundred day simple moving average is $1.61. The firm has a market cap of $147.94 million, a P/E ratio of -1.42 and a beta of 1.56.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, meeting analysts’ consensus estimates of ($0.40). Equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. boosted its stake in shares of Regulus Therapeutics by 5.3% during the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after acquiring an additional 11,701 shares during the last quarter. FMR LLC boosted its stake in shares of Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after acquiring an additional 716,000 shares during the last quarter. Finally, Vivo Capital LLC purchased a new position in shares of Regulus Therapeutics during the 1st quarter worth $14,400,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.